Start your Trading & Investing Journey with us
Join our channel for Daily Free Trades with Live analysis on Youtube, Trade Setup with Important Levels, and Important Stock Market Updates
Ravelcare IPO Review - Issue Date, Price, GMP, Subscription, Allotment, Lot Size, and Details
Ravelcare Limited operates in India’s beauty and personal care (BPC) segment through a digital-first, direct-to-consumer model. It earns revenue primarily by selling haircare, skincare, bodycare and scalpcare products through its website, e-commerce marketplaces and quick-commerce platforms. The company focuses on personalized and concern-specific formulations developed using customer data. Its products address hair fall, frizz, dryness, acne, pigmentation and other skin-and-hair-related concerns.
Ravelcare ,an Book Built Issue, amounting to ₹24.10 Crore,consisting entirely an fresh issue of 0.19 crore shares of ₹24.10 Crore.The subscription period for the Ravelcare IPO opens on December 01, 2025, and closes on December 03, 2025. The allotment is expected to be finalized on or about Thursday, December 04, 2025., and the shares will be listed on the BSE SME with a tentative listing date set on or about Monday, December 08, 2025.
The Share Price Band of Ravelcare IPO is set at ₹123 to ₹130 per equity share. The Market Capitalisation of the Ravelcare at IPO price of ₹130 per equity share will be ₹
89.17 Crores. The lot size of the IPO is 1000 shares. Retail investors are required to invest a minimum of ₹260,000, 2 lots ( 2000 shares), while the minimum investment for High-Net-Worth Individuals (HNIs) is
3 lots (
3000 shares), amounting to ₹
390,000.
Marwadi Chandarana Intermediaries Brokers Private Limited are the book running lead manager of the Ravelcare Ltd. while KFin Technologies Limited is the registrar for the issue. The Market Maker of the company is SS Corporate Securities Ltd.
Ravelcare Limited IPO GMP Today
The Grey Market Premium of Ravelcare IPO is expected to be ₹30 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.
Ravelcare Limited IPO Live Subscription Status Today: Real-Time Update
As of 05:30 PM on 02 December, 2025, the Ravelcare IPO live subscription status shows that the IPO subscribed 75.85 times on its Second Day of subscription period. Check the Ravelcare IPO Live Subscription Status Today at BSE.
Ravelcare Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Ravelcare IPO allotment date is 04 December 2025, Thursday, Ravelcare IPO Allotment will be out on 04 December 2025, Thursday.and will be live on Registrar Website from the allotment date.
Check KFin Technologies Limited IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Ravelcare IPO from the dropdown list of IPOs
- Enter your application number, PAN, or DP Client ID
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.
Objectives of Ravelcare Limited IPO
Ravelcare to utilise the Net Proceeds towards the following objects:
1. ₹1,150.00 Lakh is required for Marketing and advertisement expenses toward enhancing the awareness and visibility of our brand
2. ₹780.60 Lakh is required for Setting up a new manufacturing facility located at Mauje-Peth in Amravati (“Proposed facility”)
3. General Corporate Purposes.
Refer to Ravelcare Limited RHP for more details about the Company.
Ravelcare Limited Day Wise IPO GMP Trend
| GMP Date | Issue Price | Expected Listing Price | GMP | Last Updated |
|---|---|---|---|---|
| November 24, 2025 | N/A | N/A | ₹0(0.0%) | 24 November 2025; 05:28 PM |
| November 24, 2025 | N/A | N/A | ₹0(0.0%) | 26 November 2025; 10:43 AM |
| November 24, 2025 | N/A | N/A | ₹0(0.0%) | 02 December 2025; 04:35 PM |
| November 24, 2025 | N/A | N/A | ₹0(0.0%) | 02 December 2025; 04:49 PM |
Ravelcare IPO Details
| Market Capitalization | ₹89.17 Cr. |
| IPO Date | December 01, 2025 to December 03, 2025 |
| Listing Date | December 08, 2025 |
| Face Value | ₹10 Per Share |
| Price Band | ₹123 to ₹130 per share |
| Issue Price | ₹130 per share |
| Employee Discount | NA |
| Lot Size | 1000 Equity Shares |
| Total Issue Size | 18,54,000 Equity Shares (aggregating to ₹24.10 Cr) |
| Fresh Issue | 18,54,000 Equity Shares (aggregating to ₹24.10 Cr) |
| Offer for Sale | NA |
| Issue Type | Book Built Issue |
| Listing At | BSE SME |
| Share holding pre issue | 50,05,000 |
| Share holding post issue | 68,59,000 |
| Rating | Apply |
Ravelcare IPO Anchor Investors Details
| Bid Date | November 28, 2025 |
| Shares Offered | 5,25,000 |
| Anchor Portion Size (In Cr.) | 6.83 |
| Anchor lock-in period end date for 50% shares (30 Days) | January 03, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | March 04, 2026 |
Ravelcare IPO Timeline (Tentative Schedule)
| IPO Open Date | Mon, Dec 1, 2025 |
| IPO Close Date | Wed, Dec 3, 2025 |
| Basis of Allotment | Thu, Dec 4, 2025 |
| Initiation of Refunds | Fri, Dec 5, 2025 |
| Credit of Shares to Demat | Fri, Dec 5, 2025 |
| Listing Date | Mon, Dec 8, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Wed, Dec 3, 2025 |
Ravelcare IPO Reservation
| Investor Category | Shares Offered | Reservation % |
|---|---|---|
| QIB Portion | 880,000 | Not less than 50% of the Net Offer |
| Non-Institutional Investor Portion | 264,000 | Not more than 15% of the Net Issue |
| Retail Shares Offered | 616,000 | Not more than 35% of the Net Offer |
| Market Maker Portion | 94,000 | - |
Ravelcare IPO Promoter Holding
| Share Holding Pre Issue | 99.96% |
| Share Holding Post Issue | 72.94% |
Ravelcare IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹260,000 |
| Retail (Max) | 2 | 2,000 | ₹260,000 |
| S-HNI (Min) | 3 | 3,000 | ₹390,000 |
| S-HNI (Max) | 7 | 7,000 | ₹910,000 |
| B-HNI (Min) | 8 | 8,000 | ₹1,040,000 |
Ravelcare IPO Subscription Status
| Investor Category | Shares Offered | Shares Bid For | No of Times Subscribed | Last Upadeted |
|---|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 3,51,000 | 5,47,25,000 | 155.91x | 04 December 2025; 10:28 AM |
| Non Institutional Investors(NIIS) | 2,64,000 | 19,85,70,000 | 752.16x | 04 December 2025; 10:28 AM |
| Retail Individual Investors (RIIs) | 6,20,000 | 28,71,38,000 | 463.13x | 04 December 2025; 10:28 AM |
| Total | 12,35,000 | 54,04,33,000 | 437.60x | 04 December 2025; 10:28 AM |
About Ravelcare Limited
Ravelcare Limited operates in India’s beauty and personal care (BPC) segment through a digital-first, direct-to-consumer model. It earns revenue primarily by selling haircare, skincare, bodycare and scalpcare products through its website, e-commerce marketplaces and quick-commerce platforms. The company focuses on personalized and concern-specific formulations developed using customer data. Its products address hair fall, frizz, dryness, acne, pigmentation and other skin-and-hair-related concerns.
Key Clients & Manufacturing Facilities
The company sells directly to retail customers and does not list institutional clients. Currently, it relies fully on third-party manufacturers for all its products but plans to establish its own integrated manufacturing facility at Mauje-Peth, Amravati (Maharashtra), with a 1,050 TPA capacity. The upcoming facility will house R&D, manufacturing, packaging, warehousing and dispatch under one roof, reducing contract-manufacturing dependency and improving margins.
Product Portfolio & Order Book
Ravelcare’s portfolio spans haircare (93–95% of sales), skincare, bodycare and newly launched scalpcare. Products include shampoos, conditioners, serums, lotions and personalized treatments. These products sit at the usage and replenishment stage of the customer lifecycle, supporting recurring orders—repeat orders rose to 36.86% in FY2025. Revenue is diversified across categories, but the RHP does not mention any order book or segment-wise outstanding orders.
Mergers, Expansion Plans & Capex
The company has not undertaken any mergers or acquisitions in the last ten years. It plans a major capex project of ₹780.60 lakh for setting up an in-house manufacturing facility, covering building construction and machinery purchase. The expansion aims to reduce outsourcing costs, improve quality control, accelerate product development and enhance margins. The project is subject to statutory approvals and potential implementation delays.
Employees & Bankers
As of September, 30, 2025, our Company had a total of 20 employees. The Banker to the Company is ICICI Bank Limited.
MANAGEMENT & VISION
Ravelcare is led by promoters Ayush Mahesh Varma, Maheshkumar Ramchandra Varma and Anita Mahesh Varma. Management aims to strengthen the brand through digital-first customer acquisition, personalization and in-house manufacturing. Their near-term strategy focuses on commissioning the Amravati facility to improve margins, scale product innovation and reduce third-party dependency. Long-term targets include expanding geographical reach, increasing product categories, and enhancing D2C engagement. Capex funding will be sourced from IPO proceeds (₹780.60 lakh allocated for the project).
INDUSTRY OVERVIEW
India’s beauty and personal care (BPC) market is valued at ₹2,43,236 crore (US$ 28 billion) and expected to grow to ₹2,95,358 crore (US$ 34 billion) by 2028 at a CAGR of 10–11%. India is the world’s fastest-growing online beauty market, with e-commerce and quick-commerce sales rising 39% in value between June–November 2024, compared to just 3% growth in offline channels. Approximately 17% of Indian consumers now buy beauty products online. Major industry leaders include Amazon, Myntra, Nykaa, Blinkit, Tira and multiple D2C brands.
KEY RISK FACTORS
- High dependency on third-party manufacturers
Ravelcare fully relies on external manufacturers, exposing it to risks such as quality issues, capacity constraints, regulatory failures and delays. Limited control over production can affect product consistency and timely delivery, impacting brand trust. - Execution risk of new manufacturing facility
The proposed Amravati plant requires multiple approvals and is vulnerable to cost overruns, construction delays and machinery issues. Any failure to complete the project on time may affect expansion plans, margins and operational efficiency. - Intense competition in the BPC market
The company competes with large, well-funded brands and new D2C entrants. Competitors may offer lower prices, stronger marketing or faster innovation, potentially reducing Ravelcare’s market share and increasing promotional expenses. - Reliance on third-party logistics and technology providers
Operational disruptions at courier partners, e-commerce warehouses or digital service providers may cause delivery delays, customer dissatisfaction or data issues, negatively affecting sales and brand reputation. - Limited manufacturing experience of promoter
The promoter has limited experience in manufacturing operations, posing challenges in managing the upcoming facility efficiently and ensuring smooth transitions from outsourced to in-house production. - Revenue concentration in haircare
More than 93% of revenue comes from the haircare segment. Any slowdown in this segment, consumer preference shift or competitive pricing may significantly affect overall financial performance. - Dependency on digital sales channels
With over 95% revenue from online platforms, disruptions in marketplaces, algorithm changes, increased commissions or logistics issues can materially impact sales and customer acquisition costs.
KEY STRENGTHS & OPPORTUNITIES
- Strong digital-first D2C model
The company’s digital distribution through its website, e-commerce and quick-commerce platforms enables full control over consumer interaction, lower distribution costs and high repeat purchase rates, supporting scalable growth. - Personalized and data-driven product innovation
Customer profiling through online consultations allows the company to create personalized formulations. This enhances user experience, drives loyalty and differentiates the brand in a crowded market. - High repeat order rate improvement
Repeat customer orders increased significantly from 16.81% in FY2023 to 36.86% in FY2025, reflecting rising customer satisfaction and brand acceptance, which strengthens revenue stability. - Upcoming in-house manufacturing facility
The proposed plant will reduce outsourcing costs, improve quality control and accelerate R&D. Over time, this may expand margins and enable quicker product launches, strengthening the company’s competitive position. - Diversification across skincare, bodycare and scalpcare
While haircare dominates revenue, the company is expanding into adjacent categories with higher growth potential, improving cross-selling opportunities and reducing category concentration risk. - Strong financial performance and profitability
The company maintains healthy EBITDA margins (27–30%) and PAT margins above 21%, supported by efficient digital marketing, high D2C penetration and controlled operating costs.
Ravelcare Limited Financial Information (Restated Consolidated)
Amount in (₹ in Lakhs)
| Period Ended | Sep 30, 2025 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 |
|---|---|---|---|---|
| Reserve of Surplus | 854.16 | 534.57 | 509.06 | 6.65 |
| Total Assets | 1,567.60 | 1,163.47 | 803.35 | 174.11 |
| Total Borrowings | 0.00 | 0.00 | 3.81 | 40.53 |
| Fixed Assets | 12.88 | 16.34 | 22.08 | 1.22 |
| Cash | 172.35 | 70.45 | 11.58 | 98.31 |
| Cash flow from operating activities | -34.01 | -55.43 | 641.67 | 100.04 |
| Cash flows from investing activities | 135.92 | 118.11 | -691.67 | -1.16 |
| Cash flow from financing activities | - | -3.81 | -36.72 | -1.13 |
| Net Borrowing | -172.35 | -70.45 | -7.77 | -57.78 |
| Revenue | 1,444.38 | 2,529.80 | 2,227.88 | 349.37 |
| EBITDA | 432.65 | 681.98 | 664.11 | 50.70 |
| PAT | 319.59 | 525.52 | 502.41 | 41.47 |
| PAT Margin | 22.13% | 20.77% | 22.55% | 11.87% |
| EPS | 6.39 | 10.5 | 10.04 | 11.87% |
Note 1:- RoE, ROCE & RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Note 2:- Pre EPS and Post EPS calculation in KPI is based (Profit/Loss for the Year) on 31st Mar, 2025 Data, given in RHP.
Note 3:- RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Note 4:- Price to Book Value calculation in KPI is based on Cap Price Post Issue Data, given in FINANCIAL EXPRESS.
Key Performance Indicator
| KPI | Values |
|---|---|
| EPS Pre IPO (Rs.) | 10.5 |
| EPS Post IPO (Rs.) | 7.66 |
| Adjusted 12M EPS Post IPO (Rs.) | 9.32 |
| P/E Pre IPO | 12.38 |
| P/E Post IPO | 16.97 |
| Adjusted 12M P/E Post IPO | 13.95 |
| ROE | 68.04% |
| ROCE | 68.32% |
| P/BV | 6.29 |
| Debt/Equity | - |
| RoNW | 50.77% |
| EBITDA Margin | 27.30% |
| PAT Margin | 20.77% |
Ravelcare Limited IPO Peer Comparison
| Company Name | EPS | P/E (x) | ROE | ROCE | P/BV | Debt/Equity | RoNW (%) |
|---|---|---|---|---|---|---|---|
| Ravelcare | 7.66 | 16.97 | 68.04% | 68.32% | 6.29 | - | 50.77% |
| There are no listed peers which are in the same line of business as per RHP. | - | - | - | - | - | - | - |
Ravelcare Limited Contact Details
Ravelcare Ltd.
Off-126, Neo Corporate Plaza
Cabin B, Ramchandra Lane Extension
Malad, Mumbai
Malad, Maharashtra, 400064
Phone: +91 87792 06822
Email: pragya@ravelcare.com
Website: http://www.ravelcare.com/
Ravelcare IPO Registrar and Lead Manager(s)
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: ravelcare.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
Marwadi Chandarana Intermediaries Brokers Private Limited
Phone: +91 22 6912 0027
Email: mb@marwadichandarana.com
Website: ib.marwadichandaranagroup.com
Ravelcare IPO Review
Ravelcare Limited operates in India’s beauty and personal care (BPC) segment through a digital-first, direct-to-consumer model. It earns revenue primarily by selling haircare, skincare, bodycare and scalpcare products through its website, e-commerce marketplaces and quick-commerce platforms. The company focuses on personalized and concern-specific formulations developed using customer data. Its products address hair fall, frizz, dryness, acne, pigmentation and other skin-and-hair-related concerns.
The Company is led by Promoter, i.e., AYUSH MAHESH VARMA, MAHESHKUMAR RAMCHANDRA VARMA AND ANITA MAHESH VARMA
The Revenues from operations for the Period ended on Sep 30 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹1,444.38 Lakh, ₹2,529.80 Lakh, ₹2,227.88 Lakh, and ₹349.37 Lakh, The EBITDA for the Period ended on Sep 30 2025, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹432.65 Lakh, ₹681.98 Lakh, ₹664.11 Lakh, and ₹50.70 Lakh, The Profit after Tax for the Period ended on Sep 30 2025, 2025 and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹319.59 Lakh, ₹525.52 Lakh, ₹502.41 Lakh, and ₹41.47 Lakh, respectively. This indicates a steady growth in financial performance.
The Company Key Performance Indicates the pre-issue EPS of ₹10.5 and post-issue EPS of ₹7.66 for FY25. The pre-issue P/E ratio is 12.38x,while the post-issue P/E ratio is 16.97x against the Industry P/E ratio is NA The company's ROE for FY25 is 68.04% and RoNW is 50.77% The Annualised EPS is ₹9.32x and P/E is
13.95x. These metrics suggest that the IPO is Fairly priced.
The Grey Market Premium (GMP) of Ravelcare showing listing gains of
23.07%.Given the company's financial performance and the valuation of the IPO, we recommend Risky Investors to Apply to the Ravelcare Limited IPO for Listing gain.
Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. We also use Artificial Intelligence (AI) tools to enhance the efficiency and quality of our research services, including data retrieval, analysis, and report summarization. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit Legal our website abhayvarn.com
About the Author
CA Abhay Kumar (Also known as CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.





